Diabetes & Metabolic Medicines · LP-058
Glibenclamide Tablets
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-058Diabetes & Metabolic Medicines
- Generic identity
- GlibenclamideTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-058
- Generic identity
- Glibenclamide
- Presentation
- Tablet
- Catalogue strength
- 5 mg
- Catalogue pack
- Blister 10 x 10 tablets
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Glibenclamide.
- Dosage form: tablet.
- Catalogue strength / concentration: 5 mg.
- Catalogue pack: Blister 10 x 10 tablets.
- Catalogue category: Diabetes & Metabolic Medicines.
Layer 02 · Unresolved product-specific fields
- Exact finished-product composition, excipients and manufacturing specification.
- Micronized versus nonmicronized character, particle/formulation specification, exact strength basis and dissolution/bioavailability controls.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
Identity note
Glyburide is the US name used for glibenclamide. A current DailyMed comparator explicitly notes non-bioequivalence between certain micronized and nonmicronized strengths, so micronization cannot be inferred for LP-058.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 5 mg | Tablet | — | Blister 10 x 10 tablets | Do not infer micronized status or substitute micronized/nonmicronized glyburide/glibenclamide products by strength alone. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Glibenclamide, called glyburide in the United States, is a sulfonylurea that stimulates insulin release. It is used in selected type 2 diabetes treatment plans and can cause hypoglycaemia. It is not a replacement for insulin in type 1 diabetes or a treatment for diabetic ketoacidosis. This general educational profile does not establish Luang Pharma approved labeling or determine that this ingredient is preferable to other glucose-lowering options.
Clinical context and therapeutic role
Clinical selection considers the person’s glycaemic goals, meal pattern, kidney and liver function, age and risk of low blood glucose. Older or frail patients and those with impaired organ function may be particularly vulnerable to prolonged hypoglycaemia. The clinician evaluates alternatives and other diabetes medicines. A clear plan should cover glucose monitoring and what to do during illness, fasting or reduced food intake without relying on a website for individualized instructions.
Selected safety context
Hypoglycaemia can be severe or prolonged and may cause sweating, shakiness, confusion, seizures or unconsciousness. Marked symptoms need urgent care. Weight gain and gastrointestinal discomfort can occur. Renal or hepatic impairment, missed meals, alcohol and interacting medicines can increase risk. Some beta blockers can obscure warning symptoms. Pregnancy and glucose-6-phosphate dehydrogenase deficiency require review. The exact formulation must be confirmed; different glyburide products are not necessarily interchangeable solely by stated milligrams.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The catalogue describes a tablet presentation. The exact salt, coating, score line and release characteristics need confirmation from the authorized product information. A milligram strength identifies ingredient quantity; it does not establish whether a tablet may be split, crushed or exchanged for another formulation.
Keep the product in its labeled packaging so the batch, expiry and instructions remain identifiable. Follow the actual label for storage conditions and disposal. Do not use a damaged or unidentified tablet, and keep all medicines securely out of children’s reach.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
A diabetes-care professional should confirm the formulation, glycaemic objective, renal function and hypoglycaemia risk. The person should have an individualized monitoring and illness plan; this educational page does not supply dose-selection or conversion instructions.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Strength/form-to-pack SKU matrix and controlled packaging artwork where more than one variant is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07c checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: GlyburideArchived source classification: NLM-hosted medicine monograph | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Glyburide tablets (micronized) exampleArchived source classification: US official drug label example | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-058.
Professional enquiries
Request product-specific evidence for LP-058.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.